Following the experience with osimertinib in NSCLC patients with EGFR mutations, the second-generation ALK TKIs have replaced crizotinib as the first-line treatment for advanced-stage ALK-rearranged NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.